Celator Pharmaceuticals (CPXX) 10-K 17 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 16, 2015	Jun. 30, 2014
Document Information [Line Items]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Registrant Name	Celator Pharmaceuticals Inc
Entity Central Index Key	1327467
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$53,993,665
Trading Symbol	CPXX
Entity Common Stock, Shares Outstanding		33,741,872

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$32,413,777	$23,589,516
Restricted cash	194,561	287,657
Other receivables	21,102	1,417,313
Prepaid expenses and deposits	482,472	491,465
Assets held for sale	0	74,086
Other current assets	458,278	468,389
Total current assets	33,570,190	26,328,426
Property and equipment, net	1,004,412	1,138,579
Other assets	544,501	5,745
Total assets	35,119,103	27,472,750
Current liabilities:
Current portion of debt	284,961	0
Accounts payable	723,765	1,193,148
Accrued liabilities	1,735,420	1,630,809
Current portion of deferred revenue	542,986	542,986
Total current liabilities	3,287,132	3,366,943
Deferred revenue	45,249	588,236
Deferred rent	45,408	53,084
Loans payable	9,836,256	0
Total liabilities	13,214,045	4,008,263
Commitments and contingencies (Note 15)
Stockholders' equity
Preferred stock Authorized 20,000,000 shares, par value $0.001	0	0
Common stock Authorized 200,000,000 shares, par value $0.001 Issued and outstanding 33,681,355 and 26,035,596 shares as of December 31, 2014 and 2013 respectively	33,681	26,036
Warrants	1,083,193	1,083,193
Additional paid-in capital	171,289,703	155,953,894
Accumulated other comprehensive loss	-1,133,266	-1,133,266
Accumulated deficit	-149,368,253	-132,465,370
Total stockholders' equity	21,905,058	23,464,487
Total liabilities and stockholders' equity	$35,119,103	$27,472,750

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets [Parenthetical] (USD $)	Dec. 31, 2014	Dec. 31, 2013
Preferred Stock, Shares Authorized	20,000,000	20,000,000
peferred stock, par valur (in dollars per share)	$0.00	$0.00
Common stock, authorized shares	200,000,000	200,000,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, issued shares	33,681,355	26,035,596
Common stock, outstanding shares	33,681,355	26,035,596

Consolidated_Statements_of_Los

Consolidated Statements of Loss (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Expenses
Research and development	$11,892,368	$9,423,056
Leukemia & Lymphoma Society funding	-1,542,986	-561,086
General and administrative	7,292,159	5,427,707
Loss on disposal of property and equipment	77,624	126,633
Amortization and depreciation	195,492	197,743
Operating loss	-17,914,657	-14,614,053
Other income (expenses)
Foreign exchange loss	-31,093	-31,028
Interest and miscellaneous income	10,001	9,092
Non-cash derivative instrument charge	0	-7,473,108
Interest expense	-903,890	-147,360
Loss before income taxes	-18,839,639	-22,256,457
Income tax benefit	1,936,756	1,412,302
Net loss	($16,902,883)	($20,844,155)
Net loss per share
Basic and diluted (in dollars per share)	($0.62)	($0.95)
Weighted average of common shares outstanding
Basic and diluted (in shares)	27,422,460	22,000,476

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Warrants [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2012	$6,851,780	$13,673	$1,083,193	$118,509,395	($1,133,266)	($111,621,215)
Balance (in shares) at Dec. 31, 2012		13,673,160
Stock based compensation	538,643	0	0	538,643	0	0
Issued for cash on exercise of stock options (in shares)	8,803
Issued for cash, net of stock issuance costs	29,445,111	12,363	0	29,432,748	0	0
Issued for cash, net of stock issuance costs (in shares)		12,362,436
Derivative liability reclassificaton (See Note 9)	7,473,108	0	0	7,473,108	0	0
Net loss for the period	-20,844,155	0	0	0	0	-20,844,155
Balance at Dec. 31, 2013	23,464,487	26,036	1,083,193	155,953,894	-1,133,266	-132,465,370
Balance (in shares) at Dec. 31, 2013		26,035,596
Stock based compensation	1,350,243	0	0	1,350,243	0	0
Issued for cash on exercise of stock options	100,639	43	0	100,596	0	0
Issued for cash on exercise of stock options (in shares)	42,936	42,936
Issued for cash, net of stock issuance costs	13,571,820	7,602	0	13,564,218	0	0
Issued for cash, net of stock issuance costs (in shares)		7,602,823
Warrants issued	320,752			320,752
Net loss for the period	-16,902,883	0	0	0	0	-16,902,883
Balance at Dec. 31, 2014	$21,905,058	$33,681	$1,083,193	$171,289,703	($1,133,266)	($149,368,253)
Balance (in shares) at Dec. 31, 2014		33,681,355

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Operating activities
Net loss	($16,902,883)	($20,844,155)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization and depreciation	195,492	197,743
Non-cash stock-based compensation expense	1,350,243	538,643
Loss on disposal of property and equipment	77,624	126,633
Non-cash derivative instrument charge	0	7,473,108
Non-cash financing costs	259,926	74,752
Changes in operating assets and liabilities
Other receivables	1,392,463	586,792
Prepaid expenses and deposits	7,632	-343,190
Restricted cash	90,000	-250,049
Other current assets	10,111	-468,389
Other assets	0	25,056
Accounts payable	-462,045	492,332
Accrued liabilities	120,104	439,075
Deferred rent liability	-7,676	53,084
Deferred revenue	-542,987	-561,086
Cash used in operating activities	-14,411,996	-12,459,651
Investing activities
Purchase of property and equipment	-64,865	-92,523
Proceeds on disposals of property and equipment	0	51,776
Cash used in by investing activities	-64,865	-40,747
Financing activities
Proceeds from issuance of common stock and on options exercised	14,929,892	32,520,974
Payment of share issuance costs	-1,253,685	-3,079,611
Proceeds from loans payable	9,827,216	0
Payment of debt issuance costs	-184,469	0
Repayments of loans payable	0	-3,000,000
Cash provided by financing activities	23,318,954	26,441,363
Effect of foreign exchange rate changes	-17,832	543
Net change in cash	8,824,261	13,941,508
Cash and cash equivalents, beginning of year	23,589,516	9,648,008
Cash and cash equivalents, end of year	32,413,777	23,589,516
Supplemental disclosure of cash flow information
Interest paid	560,624	79,388
Warrants issued in connection with debt issuance costs	$320,752

Nature_of_Business_and_Liquidi

Nature of Business and Liquidity	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Nature of Operations [Text Block]	1. Nature of Business and Liquidity
	Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is a clinical stage biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. The Company’s proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination until exposure to the tumor following administration. The Company’s pipeline includes lead product, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; a preclinical stage product candidate; CPX-8 (a hydrophobic docetaxel prodrug nanoparticle formulation), being studied by the National Cancer Institute’s Nanotechnology Characterization Laboratory; and several programs exploring novel combinations of existing drugs, including molecularly targeted therapies.
	The Company has incurred recurring losses and negative cash flows from operations since inception. As of December 31, 2014, the Company had an accumulated deficit of $149.4 million. The Company expects operating losses and negative cash flows to continue for the foreseeable future until such time, if ever, that it can generate significant revenues from its product candidates currently in development. At December 31, 2014, the Company had cash and cash equivalents of $32.4 million. Management believes that the cash and cash equivalents at December 31, 2014, and cash available to the Company through the Hercules Technology Growth Capital Inc. (“Hercules”) term loan will be sufficient to meet estimated working capital requirements and fund planned operations into the second half of 2016.
	The Company is subject to those risks associated with any specialty pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. Substantial additional financing will be needed by the Company to fund its operations and to commercialize its product candidates. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies
	The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and are presented in U.S. dollars. The following is a summary of significant accounting policies used in the preparation of these consolidated financial statements.
	Basis of consolidation: The consolidated financial statements include the accounts of the company and its wholly-owned subsidiaries, Celator Pharmaceutical Corp. (“CPC”) and Celator UK Ltd. All intercompany transactions have been eliminated.
	Use of estimates: The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates. Significant areas requiring management estimates in the preparation of these consolidated financial statements include, amongst other things, assessment of other receivables, accrued liabilities, impairment and amortization of property and equipment, valuation allowance for deferred income taxes, valuation of stock-based compensation, warrants and contingencies.
	Foreign currency translation and transactions: The functional currency of the Company and its foreign subsidiary is the U.S. dollar. As such, monetary assets and liabilities of the Company’s operation denominated in a currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing as at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates prevailing at each transaction date. Expenses are translated at the average exchange rates prevailing during the year, with the exception of amortization which is translated at historical cash and cash equivalents exchange rates. Exchange gains and losses on translation are included in operations.
	Cash and cash equivalents: The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. The carrying amount of cash equivalents approximates its fair value due to its short-term nature. The Company had $29,500,819 in short-term money market accounts as of December 31, 2014.
	Property and equipment: Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows:
	Computer equipment	4 years
	Furniture and office equipment	7 years
	Laboratory equipment	10 years
	Capital lease equipment and Leasehold improvements	Lesser of useful life or term of lease
	Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The Company reviews property and equipment to assess recoverability from future operations whenever events and circumstances indicate that the carrying value may not be recoverable. Impairment losses are recognized in operating results when expected undiscounted future cash flows are less than the carrying value of the assets used or disposed of by sale. If impairment is indicated, the asset value is written down to its fair value.
	Research and development: Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, maintenance of research equipment, costs related to research collaboration and licensing agreements, the cost of services provided by outside contractors, including services related to the Company’s clinical trials, clinical trial expenses, the full cost of manufacturing drug for use in research, preclinical development, and clinical trials. All costs associated with research and development are expensed as incurred.
	Research collaboration funding: The Company has research and development agreements where the Company receives funding when it achieves certain agreed upon milestones such as meeting clinical trial objectives or patient enrollment. In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 605-28-25-2, Milestone Method-Recognition milestones considered substantive and that related solely to past Company performance and do not have any remaining deliverables associated with them are recognized as revenue when earned. Income derived from these arrangements is shown gross of research and development expenses on the consolidated statement of loss.
	Stock-based compensation: Stock based compensation transactions are recognized as compensation expense in the consolidated statement of  loss based on their fair values on the date of the grant, with the compensation expense recognized over the period in which a grantee is required to provide service in exchange for the award. The Company estimates the fair value of options granted using the Black-Scholes option valuation model. This estimate uses assumptions regarding a number of inputs that required the Company to make significant estimates and judgments. Because the Company is a relatively new publicly traded common stock the expected volatility assumption was based on industry peer information.
	Warrants: The estimated fair value of warrants is determined by using the Black-Scholes pricing model with assumptions for risk free interest rates, dividend yields, volatility factors and the contractual life of the warrants. Based on ASC 815 Derivatives and Hedging, the Company has determined that its outstanding warrants meet the criteria for equity classification.
	Loss per share: Income (loss) per share is computed using the weighted average number of common shares outstanding during the year. Diluted earnings per share would be calculated, if the Company had positive net earnings, to give effect to the potential dilution that if secured or other contracts to issue common stock were exercised or converted to common stock using the treasury stock method. The treasury stock method assumes that proceeds received from the exercise of stock options and warrants are used to repurchase common stock at the prevailing market rate.
	Income taxes:  The Company accounts for income taxes using ASC 740 Income Taxes. ASC 740 Income Taxes is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. In estimating future tax consequences, ASC 740 generally considers all expected future events other than enactments of and changes in the tax law or rates. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefits that, based on available evidence, are not expected to be realized. Valuation allowances are provided if, considering available evidence, it is more likely than not that the deferred tax assets will not be realized. ASC 740 clarifies the criteria that must be met prior to recognition of the financial statement benefit of a position taken in a tax return. ASC 740 provides a benefit recognition model with a two-step approach consisting of “more-likely-than-not” recognition criteria, and a measurement attribute that measures a given tax position as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. ASC 740 also requires the recognition of liabilities created by differences between tax positions taken in a tax return and amounts recognized in the financial statements.
	Investment tax credits relating to scientific research and experimental development are accounted for in operations. To the extent there is reasonable assurance the credits will be realized, they are recorded in the period the related expenditure is made as a reduction of current operating expenses (tax recovery).
	Fair value of financial instruments:  The carrying values of certain Company’s financial instruments, including cash equivalents, restricted cash, other receivables and accounts payable approximate fair value due to the short-term nature of those investments. The Company believes that the current carrying amount of its long-term debt approximates fair value because interest rate on this instrument is similar to rates that the Company would be able to receive for similar instruments of comparable maturity.
	ASC 820 Fair Value Measurements defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.
	ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820-10 establishes three levels of inputs that may be used to measure fair value:
	Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
	Level 2 applies to assets or liabilities for which there are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
	Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.
	ASC 820, Fair Value Measurements requires disclosures about transfers into and out of Levels 1 and 2 and separate disclosures about purchases, sales, issuances, and settlements relating to Level 3 measurements. It also clarifies existing fair value disclosures regarding the level of disaggregation and the inputs and valuation techniques used to measure fair value.
	The Company recognizes transfers between input levels as of the actual date of event. There were no transfers between levels and the following table provides the assets carried at fair value:
		Fair Value		(Level 1)		(Level 2)		(Level 3)
	31-Dec-14
	Assets:
	Money Market Fund	$	29,500,819	$	29,500,819	$	—	$	—
	31-Dec-13
	Assets:
	Certificates of Deposit	$	15,003,472	$	15,003,472	$	—	$	—
	Money Market Fund		7,597,730		7,597,730		—		—
	Total	$	22,601,202	$	22,601,202	$	—	$	—
	Segment reporting: The Company operates within one reportable segment and presents geographic results of its United States and Canadian operations. Intersegment transactions and balances have been eliminated in the preparation of the segmental analysis note.
	New Accounting Pronouncement:  In June 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-10, Elimination of Certain Financial Reporting Requirements, including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation, which eliminates all incremental financial reporting requirements for development stage entities by removing ASC Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification. The amendments in this Update remove the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASC Topic 915 is removed effective for annual periods beginning after December 15, 2014 and early adoption is permitted. The Company adopted the ASU effective with the issuance of its June 30, 2014 financial statements.
	In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements — Going Concern (Subtopic 205-40). The ASU provides U.S. GAAP guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.
	In March 2013, FASB issued an amendment to the accounting guidance on foreign currency matters in order to clarify the guidance for the release of cumulative translation adjustments. The guidance is effective for interim and annual periods beginning on or after December 15, 2013. The adoption of this amended accounting guidance did not have any impact on the Company’s consolidated financial position and results of operations.

Other_Receivables

Other Receivables	12 Months Ended
	Dec. 31, 2014
Other Receivables, Net, Current [Abstract]
Other Receivable [Text Block]	3. Other Receivables
	Other receivables as of December 31, 2014 and 2013, consists of the following:
		2014		2013
	Receivables related to the sale of New Jersey net operating losses	$	—	$	1,412,302
	Other receivables		21,102		5,011
		$	21,102	$	1,417,313

Other_Current_Assets

Other Current Assets	12 Months Ended
	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets [Text Block]	4. Other Current Assets
	Other current assets as of December 31, 2014 and 2013, consists of the following:
		2014		2013
	Clinical trial materials	$	458,278	$	468,389

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property Plant And Equipment [Abstract]
Property Plant And Equipment Disclosure [Text Block]	5. Property and Equipment
	Property and equipment as of December 31, 2014 and 2013, including assets held under capital lease, consists of the following:
		2014		2013
	Computer and equipment	$	144,138	$	136,498
	Furniture and office equipment		96,457		96,457
	Laboratory equipment		1,723,331		1,760,633
	Capital lease equipment		155,524		155,523
	Leaseholds		37,789		37,789
			2,157,239		2,186,900
	Less: Accumulated depreciation		-1,152,827		-1,048,321
		$	1,004,412	$	1,138,579
	During the years ended December 31, 2014 and 2013, depreciation and amortization expense was $195,492 and $197,743 respectively.
	In February 2012, the Company closed a laboratory and consigned certain property and equipment for sale with net book value of $507,622. During 2014, the Company wrote off the net book value of the remaining consigned equipment of $74,086. The Company determined that the carrying amount of these assets as of December 31, 2014 was not recoverable and less than the fair value less the cost to sell.
	During 2014, the Company wrote off other property and equipment and incurred a loss of $3,538. In 2013, assets with a net book value of $177,827 were sold for proceeds of $51,776, resulting in a loss on disposal of $126,051. During 2013, the also Company wrote off other property and equipment and incurred a loss of $582.

Other_Assets

Other Assets	12 Months Ended
	Dec. 31, 2014
Other Assets, Noncurrent Disclosure [Abstract]
Other Assets Disclosure [Text Block]	6. Other Assets
	Other assets as of December 31, 2014 and 2013 consist of the following:
		2014		2013
	Deferred financing costs (see Note 8)	$	539,296	$	—
	Other non-current assets		5,205		5,745
		$	544,501	$	5,745

Accrued_Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2014
Payables And Accruals [Abstract]
Accounts Payable And Accrued Liabilities Disclosure [Text Block]	7. Accrued Liabilities
	Accrued liabilities as of December 31, 2014 and 2013, consists of the following:
		2014		2013
	Accrued bonuses	$	816,144	$	624,472
	Accrued salaries and vacation		152,700		143,484
	Accrued professional fees		8,904		30,911
	Accrued clinical trial expenses		633,395		636,497
	Interest payable		83,958		—
	Accrued other		40,319		195,445
		$	1,735,420	$	1,630,809

Loans_Payable

Loans Payable	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	8. Loans Payable
	On May 9, 2014, the Company entered into a term loan agreement for $15 million with Hercules. The first $10 million of the term loan was funded at closing, and is repayable in installments over forty-eight months including an initial interest-only period of eighteen months after closing. The remaining $5 million of the term loan can be drawn down at the Company’s option at any time until March 31, 2015. Interest is payable monthly at the greater of 9.75% or an adjusted rate based upon the US prime rate with interest only period until December 1, 2015. The funds will be used to provide general working capital.
	Pursuant to the loan agreement, the Company issued Hercules a warrant to purchase 158,006 shares of the Company’s common stock at an exercise price of $2.67 per share with a term of five years. The fair value of the warrants of $320,752 and financing costs of $357,253 incurred in connection with the term loan were recorded as debt issuance costs and will be amortized as interest expense using the effective interest method over the term of the loan. Amortization of debt issuance costs was $138,709 for the year ended December 31, 2014 and the remaining unamortized debt issuance costs of $539,296 are included in other non-current assets.
	In addition, the Company will pay an end of term charge of $592,500 on the earliest to occur of (i) the term loan maturity date, (ii) the date that the Company prepays the outstanding loan, or (iii) the date that the loan become due and payable. The end of term charge will be accrued as additional interest expense using the effective interest rate method over the term of the loan. The Company accrued $121,217 of this fee during the year ended December 31, 2014.
	Long-term debt as of December 31, 2014 consists of the following:
	Loan payable	$	10,000,000
	End of term fee		121,217
			10,121,217
	Less: Current portion		-284,961
	Long-term debt	$	9,836,256

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	9. Stockholders’ Equity
	Public Offering of Common Stock and Warrants to Purchase Common Stock
	On October 28, 2014, the Company completed a public offering of 7,602,823 shares of common stock and warrants to purchase up to 760,282 shares of its common stock, including the exercise in full of the underwriters’ overallotment option to purchase up to an additional 991,673 shares of common stock and warrants to purchase 99,167 shares of common stock. The shares of common stock and warrants were offered in units consisting of one share of common stock and a warrant to purchase 0.10 of a share of common stock at a price of $1.95 per unit. The Company received approximately $13.6 million in net proceeds from the public offering after payment of fees, expenses and underwriting expenses. The shares of common stock and the warrants were immediately separable and were issued separately. The warrants have an exercise price of $3.58 per share and have a term of five years. In addition, the Company issued to the underwriters, underwriter warrants to purchase 114,042 shares of common stock at an exercise price of $3.58 per share.
	Private Placement
	On April 29, 2013, the Company entered into a securities purchase agreement and subscription agreements with certain accredited investors for the issuance and sale in the final round of a private placement of 10,430,034 shares of common stock, which the Company sold at a price of $3.116 per share for aggregate gross proceeds of $32,499,986. Warrants to purchase 0.28 shares of common stock at $3.58 per share were issued for each share of common stock purchased. The net proceeds totaled $29,420,375 for this financing.
	In connection with this final closing of the financing, 1,923,599 shares of common stock and 161,327 warrants to purchase shares of common stock at $5.21 and 1,056,898 warrants to purchase shares of common stock at $3.58 per share were issued to certain existing stockholders of the Company who participated in earlier closings of this financing. The fair value of these common shares and warrants was recognized as a derivative liability with a corresponding charge to the statement of loss. The derivative liability was fair valued at $7,473,108 and the fair value was measured using significant unobservable inputs (Level 3). Upon the final closing of the April 2013 private placement, the derivative liability was reclassified into stockholders’ equity as the obligation to issue additional securities no longer existed.
	Warrants
	The following table summarizes the warrants outstanding to purchase common stock at December 31, 2014:
	Issue date	Number of		Exercise		Term
		warrants		price
	Mar-09		12,445	$	11.25	7 years
	Dec-11		123,585	$	5.21	7 years
	Feb-12		3,700	$	5.21	6 years
	Jun-12		17,267	$	5.21	7 years
	Aug-12		112,536	$	5.21	7 years
	Apr-13		161,327	$	5.21	7 years
	Apr-13		3,977,290	$	3.58	7 years
	May-14		158,006	$	2.67	5 years
	Oct-14		874,324	$	3.58	5 years
			5,440,480

Stock_Based_Compensation

Stock Based Compensation	12 Months Ended
	Dec. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	10. Stock Based Compensation
	2013 Equity Incentive Plan
	In 2013, the Company adopted the Celator Pharmaceuticals, Inc. 2013 Equity Incentive Plan (the “Plan”) and the number of shares authorized for awards of equity options or other equity instruments under this Plan are 4,205,847. At December 31, 2014, 1,200,560 stock options remain available to be granted. The Company has reserved shares of its common stock to permit exercise of options in accordance with the terms of the Plan.
	Options granted under the Plan may be incentive stock options or non-qualified stock options. Incentive stock options may only be granted to employees. The board of directors, or a committee of the board of directors appointed to administer the Plan, determines the period over which options become exercisable and the conditions under which stock awards are granted and become vested.
	The following table summarizes the activity of the Company stock option plans for the years ended December 31, 2014 and 2013:
				Number of			Weighted			Weighted Average			Aggregate
				options			Average			Remaining			Intrinsic Value
							Exercise price			Contractual Life
										(Yrs)
	Outstanding at	1-Jan-13			806,788		$	2.52
		Granted			1,864,559			3.18
		Exercised			-8,803			2.81
		Cancelled			-84,292			2.98
	Outstanding at	31-Dec-13			2,578,252		$	2.98
		Granted			502,100			3.13
		Exercised			-42,936			2.34
		Cancelled			-32,129			2.97
	Outstanding at	31-Dec-14			3,005,287		$	3.02			7.2		$	9,801
	Exercisable at	31-Dec-14			1,352,056		$	2.82			5.3		$	9,771
	The following table summarizes stock options outstanding as of December 31, 2014:
	Range of	Number			Average			Remaining			Number			Average
	exercise price	outstanding			exercise			contractual			exercisable			exercise
					price			life (years)						price
	$1.12 - $1.95		14,632		$	1.29			6.6			11,632		$	1.12
	$2.25 - $3.40		2,672,246			2.96			7			1,258,100			2.79
	$3.47 - $3.80		318,409			3.52			8.9			82,324			3.51
			3,005,287		$	3.02			7.2			1,352,056		$	2.82
	A summary of unvested awards activity during the year ended December 31, 2014 is as follows:
		Number			Grant date
					fair value
	1-Jan-14		1,810,203		$	4,146,515
	Granted		502,100			1,343,817
	Vested		-659,072			-1,478,969
	31-Dec-14		1,653,231		$	4,011,363
	The following table provides information regarding stock options activity for the year ended December 31, 2014 and 2013:
		Year ended December 31,
		2014				2013
	Stock compensation expense recognized	$	1,350,243			$	538,643
	Weighted average grant-date fair value of stock options issued (per share)	$	2.68			$	2.29
	Grant-date fair value of stock options issued	$	1,343,817			$	4,266,120
	Intrinsic value of stock options exercised	$	32,892			$	2,566
	Volatility		114.4	%			117.7	%
	Risk-free interest rate		2	%			1.9	%
	Dividend yield		0	%			0	%
	Expected life in years		6.2				6.2
	The grant-date fair value of stock options is estimated using the Black Scholes option pricing model. The Company determined the options’ life based on the simplified method and determined the options’ expected volatility based on peer group volatility and dividend yield based on the historical dividend payments. The risk free interest rate is based on the yield of an applicable term Treasury instrument.
	The Company amortizes the fair value of the stock options on a straight-line basis over the applicable requisite service periods of the awards, which is generally the vesting period. At December 31, 2014, the total compensation cost related to non-vested awards not yet recognized and weighted average period over which it will be recognized was $3,641,722 and 2.6 years, respectively.

Benefit_Plans

Benefit Plans	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	11. Benefit Plans
	The Company has a domestic employee 401K savings plan. Beginning in 2014, the Company matches 50% of each employee’s contribution up to a maximum of 6% of the employee’s earnings for contributions made to the domestic 401K savings plan and to individual registered retirement savings plans in Canada. The Company’s matching contributions to the savings plan were $111,509 in 2014.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	12	Income Taxes
	Loss before income taxes consisted of the following:
			Year ended December 31,
			2014			2013
	Domestic		$	-16,710,376		$	-20,038,881
	Foreign			-2,129,263			-2,217,576
	Total		$	-18,839,639		$	-22,256,457
	A reconciliation of the Statutory United States federal income tax rate to the Company’s effective rate and for December 31, 2014 and 2013 is as follows:
			Year ended December 31,
			2014				2013
	Loss before income taxes		$	-18,839,639			$	-22,256,457
	Federal rate			34	%			34	%
	US Federal statutory tax rate			6,405,477				7,567,195
	State, net of federal rate			837,307				487,083
	Permanent differences			-1,030,698				-2,548,770
	Research and development tax credits			833,271				72,377
	Other			386,594				-113,803
	Changes to valuation allowances			-5,495,195				-4,051,780
			$	1,936,756			$	1,412,302
	In 2014 and 2013, the Company was approved to sell New Jersey net operating loss carryforwards (“NOLS”) under the New Jersey Technology Business Tax Certificate Transfer Program, which resulted in the recognition of an income tax benefit of $1,936,756 and $1,412,302, respectively.
	Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting purposes and tax purposes, and net operating loss and tax credit carry forwards. Significant components of the Company’s total deferred tax asset as of December 31, 2014 and 2013 are as follows:
			December 31,
			2014			2013
	Net operating loss carry forwards		$	43,176,150		$	38,619,755
	Research and development loss pool carry forwards			3,512,452			3,865,195
	Deferred revenue			229,410			384,615
	Accrued expenses and other			440,342			287,272
	Stock based compensation			1,094,135			529,645
	Property and equipment			-267,909			-366,186
	R&D and investment tax credit carry forwards			1,125,434			494,523
	Deferred tax assets		$	49,310,014		$	43,814,819
	Deferred tax assets valuation allowance		$	-49,310,014		$	-43,814,819
			$	—		$	—
	The valuation allowance at December 31, 2014 and 2013 was primarily related to R&D investment tax credits carryforwards and expenditures, federal and state net operating loss carryforwards that, in the judgment of management, are not more-likely-than-not to be realized. In assessing the realizability of deferred tax assets, management considers whether it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.
	At December 31, 2014, the Company had net operating loss carryforwards for Federal income tax purposes of $124,704,785 which are available to offset future Federal taxable income, if any, through 2022. The company has U.S. Research and Development tax credits carryforwards for federal income tax purposes of $674,435 which are available to offset future federal tax liability, if any, through 2025. The Company has net operating loss carryforwards for state income tax purposes of $15,530,804 which are available to offset future state taxable income through 2034.
	At December 31, 2014 and 2013, the Company had Canadian federal investment tax credits of approximately $450,999 and $494,523, respectively, available to reduce taxes payable through 2030. The Company has no Canadian tax loss carry forwards.

Geographic_Segment_Information

Geographic Segment Information	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	13. Geographic Segment Information
	The Company operates in the United States and Canada. The Company’s CPX-351 clinical trial materials are manufactured by a third party using the Company’s equipment located in Germany. Geographic net loss information is based on the location whereby the expenses were incurred. The geographic information about total assets is based on the physical location of the assets.
		Total Assets
		December 31,
		2014		2013
	United States	$	34,027,837	$	26,190,516
	Canada		223,572		284,563
	Germany		867,694		997,671
	Total Assets	$	35,119,103	$	27,472,750
		Net Loss
		Year ended December 31,
		2014		2013
	United States	$	-14,773,620	$	-18,626,579
	Canada		-2,129,263		-2,217,576
	Total Net Loss	$	-16,902,883	$	-20,844,155

Leukemia_and_Lymphoma_Society_

Leukemia and Lymphoma Society funding	12 Months Ended
	Dec. 31, 2014
Research and Development [Abstract]
Research And Development And License Agreement [Text Block]	14. Leukemia and Lymphoma Society funding
	In June 2012, the Company entered into an agreement with the Leukemia & Lymphoma Society® (“LLS”) pursuant to which LLS has agreed to provide up to $5.0 million in funding from the LLS Therapy Acceleration Program (“TAP program”) for the Phase 3 clinical study of the Company’s lead compound CPX-351. Upon execution of the agreement, the Company received an upfront payment of $2.0 million and may receive further payments of $3.0 million upon the achievement of clinical milestones. The Company recorded the $2.0 million upfront payment as deferred revenue which will be recognized on a straight-line basis over the estimated performance period of the funding agreement. During the years ended December 31, 2014 and 2013, the Company recognized $542,986 and $561,086, respectively related to the amortization of the upfront payment. The estimated performance period is expected to be complete in January 2016. During 2014, the Company met two separate milestones under the agreement which resulted in the recognition of $1.0 million which was recorded as Leukemia & Lymphoma Society funding. The agreement remains in effect until the completion of the milestones unless terminated earlier in accordance with the provisions in the agreement. The Company may terminate the agreement at any time during its term upon at least 30 days’ prior written notice to LLS or upon written notice to LLS upon the termination of the CPX-351 program. LLS may terminate this agreement upon 90 days prior written notice to the Company. Funding under the agreement is exclusively for use in support of the clinical development activities of the research program. Provided the Company believes the product is safe and effective, the Company has agreed that, for a period of five years following the expiration or termination of the agreement, the Company will take such steps as are commercially reasonable to further the clinical development of the product and to bring the product to practical application for Acute Myeloid Leukemia.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Commitments And Contingencies Disclosure [Text Block]	15. Commitments and Contingencies
	In September 2014, the Company entered into a lease agreement for a laboratory space in Vancouver, British Columbia, which expires in September 2015. The remaining minimum lease payments as of December 31, 2014 were $25,087.
	In March 2013, the Company entered into an office lease agreement for office space in Ewing, New Jersey, which commenced in June 2013 with a term of sixty months. The remaining minimum lease payments as of December 31, 2014 were $495,840. Under the Ewing, New Jersey lease agreement, the Company will be obligated to maintain a letter of credit from a bank with respect to its security deposit obligations in the amount of $200,000 during the first year of the Agreement, which amount will be reduced by $40,000 per year on each of December 1, 2014, 2015, and 2016 and by $60,000 on December 1, 2017.
	In February 2013, the Company renewed its office lease agreements for office space in Vancouver, British Columbia, effective April 1, 2013, which expires in June 2016. The remaining minimum lease payments as of December 31, 2014 were $93,292.
	Rent expense amounted to $221,867 in 2014 and $246,784 in 2013. Minimum lease payments on all operating leases are as follows:
	Year ending December 31,
	2015	$	232,932
	2016		177,013
	2017		145,475
	2018		72,372
	Total	$	627,792
	The Company has a worldwide exclusive license agreement with Princeton University dated June 2007 that provides the Company with exclusive rights to some aspects of its nanoparticle polymer technology arising from research sponsored by the Company at Princeton University between 2003 and 2007. These inventions are generally characterized as particulate constructs for release of active agents for medical application. Of the products currently in the Company’s pipeline, only the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation is subject to this agreement. The Company is obligated to pay a royalty on net sales to Princeton University of a low single-digit percentage if any invention is sold by the Company or a company to which the product covered by the invention was licensed by the Company, which was generated under the exclusive licensing agreement. No royalty or other product/sub-license-related payments have been made to date. The Company is obligated to provide Princeton University a percentage within the range of 45% to 55% of proceeds obtained from a sub-license of the intellectual property to a third party in cases where the Company has not conducted any research or development activities and is solely licensing out the original intellectual property jointly developed by the Company and Princeton University. The Company may terminate the agreement at any time by giving 90 days written notice to Princeton University. Princeton may terminate the agreement if the Company should breach or fail to perform under the agreement, with written notice of default provided by Princeton University to the Company and only if the Company fails to cure the default within 60 days. The Company is obligated under the agreement to provide an annual progress report to Princeton University on any developments of the licensed technology as well as prosecution of the patents covering the technology and the use of commercially reasonable efforts to develop licensed products.
	The Company has a collaborative research agreement dated May 2001 with the British Columbia Cancer Agency (“BCCA”) whereby in consideration for the license and conditional assignment of all Company-sponsored intellectual property to the Company by BCCA, the Company will pay to BCCA a royalty in the low single digits on net sales of royalty-bearing products in territories so long as a valid claim exists for inventions made between June 2000 and June 2005 under the agreement. All obligations relating to the conduct of the research and assignment of intellectual property have been completed. No payments of royalties have been made to date. Either party may terminate the agreement if the other party commits a material breach or default and such breach or default is not reasonably cured within 45 days.
	In consideration of funding by LLS and transfer to the Company of any rights LLS may have to any project inventions developed during the term of the agreement, the Company may be required to pay LLS a cash multiple on the LLS funding, (LLS funding is the $5 million in support of the Phase 3 study in addition to the approximately $4.1 million the Company received in support of the Phase 2 study). Subject to exclusions under the agreement, the Company is obligated to pay LLS an amount equal to 50% of the cash payments the Company receives from out-licenses and transfers of rights to the product or other liquidity event, as defined in the agreement, until LLS has received an amount equal to 1.5 times the amount of funding the Company receives from LLS. The total amount payable by the Company to LLS will not exceed 3.55 times the amount of funding received from LLS, with the specific amount depending on when the payment(s) occur relative to the timing of the research program and product commercialization. The payments may take the form of cash payments or royalties (not to exceed 5% of net sales) but will not exceed the maximum amount referred to in the preceding sentence.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Basis of consolidation: The consolidated financial statements include the accounts of the company and its wholly-owned subsidiaries, Celator Pharmaceutical Corp. (“CPC”) and Celator UK Ltd. All intercompany transactions have been eliminated.
Use of Estimates, Policy [Policy Text Block]	Use of estimates: The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates. Significant areas requiring management estimates in the preparation of these consolidated financial statements include, amongst other things, assessment of other receivables, accrued liabilities, impairment and amortization of property and equipment, valuation allowance for deferred income taxes, valuation of stock-based compensation, warrants and contingencies.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation and transactions: The functional currency of the Company and its foreign subsidiary is the U.S. dollar. As such, monetary assets and liabilities of the Company’s operation denominated in a currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing as at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates prevailing at each transaction date. Expenses are translated at the average exchange rates prevailing during the year, with the exception of amortization which is translated at historical cash and cash equivalents exchange rates. Exchange gains and losses on translation are included in operations.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents: The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. The carrying amount of cash equivalents approximates its fair value due to its short-term nature. The Company had $29,500,819 in short-term money market accounts as of December 31, 2014.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment: Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows:
	Computer equipment	4 years
	Furniture and office equipment	7 years
	Laboratory equipment	10 years
	Capital lease equipment and Leasehold improvements	Lesser of useful life or term of lease
	Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The Company reviews property and equipment to assess recoverability from future operations whenever events and circumstances indicate that the carrying value may not be recoverable. Impairment losses are recognized in operating results when expected undiscounted future cash flows are less than the carrying value of the assets used or disposed of by sale. If impairment is indicated, the asset value is written down to its fair value.
Research and Development Expense, Policy [Policy Text Block]	Research and development: Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, maintenance of research equipment, costs related to research collaboration and licensing agreements, the cost of services provided by outside contractors, including services related to the Company’s clinical trials, clinical trial expenses, the full cost of manufacturing drug for use in research, preclinical development, and clinical trials. All costs associated with research and development are expensed as incurred.
Collaborative Arrangement, Accounting Policy [Policy Text Block]	Research collaboration funding: The Company has research and development agreements where the Company receives funding when it achieves certain agreed upon milestones such as meeting clinical trial objectives or patient enrollment. In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 605-28-25-2, Milestone Method-Recognition milestones considered substantive and that related solely to past Company performance and do not have any remaining deliverables associated with them are recognized as revenue when earned. Income derived from these arrangements is shown gross of research and development expenses on the consolidated statement of loss.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-based compensation: Stock based compensation transactions are recognized as compensation expense in the consolidated statement of  loss based on their fair values on the date of the grant, with the compensation expense recognized over the period in which a grantee is required to provide service in exchange for the award. The Company estimates the fair value of options granted using the Black-Scholes option valuation model. This estimate uses assumptions regarding a number of inputs that required the Company to make significant estimates and judgments. Because the Company is a relatively new publicly traded common stock the expected volatility assumption was based on industry peer information.
Derivatives, Policy [Policy Text Block]	Warrants: The estimated fair value of warrants is determined by using the Black-Scholes pricing model with assumptions for risk free interest rates, dividend yields, volatility factors and the contractual life of the warrants. Based on ASC 815 Derivatives and Hedging, the Company has determined that its outstanding warrants meet the criteria for equity classification.
Earnings Per Share, Policy [Policy Text Block]	Loss per share: Income (loss) per share is computed using the weighted average number of common shares outstanding during the year. Diluted earnings per share would be calculated, if the Company had positive net earnings, to give effect to the potential dilution that if secured or other contracts to issue common stock were exercised or converted to common stock using the treasury stock method. The treasury stock method assumes that proceeds received from the exercise of stock options and warrants are used to repurchase common stock at the prevailing market rate.
Income Tax, Policy [Policy Text Block]	Income taxes:  The Company accounts for income taxes using ASC 740 Income Taxes. ASC 740 Income Taxes is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. In estimating future tax consequences, ASC 740 generally considers all expected future events other than enactments of and changes in the tax law or rates. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefits that, based on available evidence, are not expected to be realized. Valuation allowances are provided if, considering available evidence, it is more likely than not that the deferred tax assets will not be realized. ASC 740 clarifies the criteria that must be met prior to recognition of the financial statement benefit of a position taken in a tax return. ASC 740 provides a benefit recognition model with a two-step approach consisting of “more-likely-than-not” recognition criteria, and a measurement attribute that measures a given tax position as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. ASC 740 also requires the recognition of liabilities created by differences between tax positions taken in a tax return and amounts recognized in the financial statements.
	Investment tax credits relating to scientific research and experimental development are accounted for in operations. To the extent there is reasonable assurance the credits will be realized, they are recorded in the period the related expenditure is made as a reduction of current operating expenses (tax recovery).
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair value of financial instruments:  The carrying values of certain Company’s financial instruments, including cash equivalents, restricted cash, other receivables and accounts payable approximate fair value due to the short-term nature of those investments. The Company believes that the current carrying amount of its long-term debt approximates fair value because interest rate on this instrument is similar to rates that the Company would be able to receive for similar instruments of comparable maturity.
	ASC 820 Fair Value Measurements defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.
	ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820-10 establishes three levels of inputs that may be used to measure fair value:
	Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
	Level 2 applies to assets or liabilities for which there are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
	Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.
	ASC 820, Fair Value Measurements requires disclosures about transfers into and out of Levels 1 and 2 and separate disclosures about purchases, sales, issuances, and settlements relating to Level 3 measurements. It also clarifies existing fair value disclosures regarding the level of disaggregation and the inputs and valuation techniques used to measure fair value.
	The Company recognizes transfers between input levels as of the actual date of event. There were no transfers between levels and the following table provides the assets carried at fair value:
		Fair Value		(Level 1)		(Level 2)		(Level 3)
	31-Dec-14
	Assets:
	Money Market Fund	$	29,500,819	$	29,500,819	$	—	$	—
	31-Dec-13
	Assets:
	Certificates of Deposit	$	15,003,472	$	15,003,472	$	—	$	—
	Money Market Fund		7,597,730		7,597,730		—		—
	Total	$	22,601,202	$	22,601,202	$	—	$	—
Segment Reporting, Policy [Policy Text Block]	Segment reporting: The Company operates within one reportable segment and presents geographic results of its United States and Canadian operations. Intersegment transactions and balances have been eliminated in the preparation of the segmental analysis note.
New Accounting Pronouncements, Policy [Policy Text Block]	New Accounting Pronouncement:  In June 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-10, Elimination of Certain Financial Reporting Requirements, including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation, which eliminates all incremental financial reporting requirements for development stage entities by removing ASC Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification. The amendments in this Update remove the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASC Topic 915 is removed effective for annual periods beginning after December 15, 2014 and early adoption is permitted. The Company adopted the ASU effective with the issuance of its June 30, 2014 financial statements.
	In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements — Going Concern (Subtopic 205-40). The ASU provides U.S. GAAP guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.
	In March 2013, FASB issued an amendment to the accounting guidance on foreign currency matters in order to clarify the guidance for the release of cumulative translation adjustments. The guidance is effective for interim and annual periods beginning on or after December 15, 2013. The adoption of this amended accounting guidance did not have any impact on the Company’s consolidated financial position and results of operations.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Fair Value, by Balance Sheet Grouping [Table Text Block]	The Company recognizes transfers between input levels as of the actual date of event. There were no transfers between levels and the following table provides the assets carried at fair value:
		Fair Value		(Level 1)		(Level 2)		(Level 3)
	31-Dec-14
	Assets:
	Money Market Fund	$	29,500,819	$	29,500,819	$	—	$	—
	31-Dec-13
	Assets:
	Certificates of Deposit	$	15,003,472	$	15,003,472	$	—	$	—
	Money Market Fund		7,597,730		7,597,730		—		—
	Total	$	22,601,202	$	22,601,202	$	—	$	—

Other_Receivables_Tables

Other Receivables (Tables)	12 Months Ended
	Dec. 31, 2014
Other Receivables, Net, Current [Abstract]
Schedule Of Other Receivables [Table Text Block]	Other receivables as of December 31, 2014 and 2013, consists of the following:
		2014		2013
	Receivables related to the sale of New Jersey net operating losses	$	-	$	1,412,302
	Other receivables		21,102		5,011
		$	21,102	$	1,417,313

Other_Current_Assets_Tables

Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Current Assets [Table Text Block]	Other current assets as of December 31, 2014 and December 31, 2013 consist of the following:
		2014		2013
	Clinical trial materials	$	458,278	$	468,389

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property Plant And Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of December 31, 2014 and 2013, including assets held under capital lease, consists of the following:
		2014		2013
	Computer and equipment	$	144,138	$	136,498
	Furniture and office equipment		96,457		96,457
	Laboratory equipment		1,723,331		1,760,633
	Capital lease equipment		155,524		155,523
	Leaseholds		37,789		37,789
			2,157,239		2,186,900
	Less: Accumulated depreciation		-1,152,827		-1,048,321
		$	1,004,412	$	1,138,579

Other_Assets_Tables

Other Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Other Assets, Noncurrent Disclosure [Abstract]
Schedule of Other Assets, Noncurrent [Table Text Block]	Other assets as of December 31, 2014 and 2013 consist of the following:
		2014		2013
	Deferred financing costs (see Note 8)	$	539,296	$	—
	Other non-current assets		5,205		5,745
		$	544,501	$	5,745

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Payables And Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued liabilities as of December 31, 2014 and 2013, consists of the following:
		2014		2013
	Accrued bonuses	$	816,144	$	624,472
	Accrued salaries and vacation		152,700		143,484
	Accrued professional fees		8,904		30,911
	Accrued clinical trial expenses		633,395		636,497
	Interest payable		83,958		—
	Accrued other		40,319		195,445
		$	1,735,420	$	1,630,809

Loans_Payable_Tables

Loans Payable (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Long-term debt as of December 31, 2014 consists of the following:
	Loan payable	$	10,000,000
	End of term fee		121,217
			10,121,217
	Less: Current portion		-284,961
	Long-term debt	$	9,836,256

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The following table summarizes the warrants outstanding to purchase common stock at December 31, 2014:
	Issue date	Number of		Exercise		Term
		warrants		price
	Mar-09		12,445	$	11.25	7 years
	Dec-11		123,585	$	5.21	7 years
	Feb-12		3,700	$	5.21	6 years
	Jun-12		17,267	$	5.21	7 years
	Aug-12		112,536	$	5.21	7 years
	Apr-13		161,327	$	5.21	7 years
	Apr-13		3,977,290	$	3.58	7 years
	May-14		158,006	$	2.67	5 years
	Oct-14		874,324	$	3.58	5 years
			5,440,480

Stock_Based_Compensation_Table

Stock Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes the activity of the Company stock option plans for the years ended December 31, 2014 and 2013:
				Number of			Weighted			Weighted Average			Aggregate
				options			Average			Remaining			Intrinsic Value
							Exercise price			Contractual Life
										(Yrs)
	Outstanding at	1-Jan-13			806,788		$	2.52
		Granted			1,864,559			3.18
		Exercised			-8,803			2.81
		Cancelled			-84,292			2.98
	Outstanding at	31-Dec-13			2,578,252		$	2.98
		Granted			502,100			3.13
		Exercised			-42,936			2.34
		Cancelled			-32,129			2.97
	Outstanding at	31-Dec-14			3,005,287		$	3.02			7.2		$	9,801
	Exercisable at	31-Dec-14			1,352,056		$	2.82			5.3		$	9,771
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table summarizes stock options outstanding as of December 31, 2014:
	Range of	Number			Average			Remaining			Number			Average
	exercise price	outstanding			exercise			contractual			exercisable			exercise
					price			life (years)						price
	$1.12 - $1.95		14,632		$	1.29			6.6			11,632		$	1.12
	$2.25 - $3.40		2,672,246			2.96			7			1,258,100			2.79
	$3.47 - $3.80		318,409			3.52			8.9			82,324			3.51
			3,005,287		$	3.02			7.2			1,352,056		$	2.82
Schedule of Nonvested Share Activity [Table Text Block]	A summary of unvested awards activity during the year ended December 31, 2014 is as follows:
		Number			Grant date
					fair value
	1-Jan-14		1,810,203		$	4,146,515
	Granted		502,100			1,343,817
	Vested		-659,072			-1,478,969
	31-Dec-14		1,653,231		$	4,011,363
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The following table provides information regarding stock options activity for the year ended December 31, 2014 and 2013:
		Year ended December 31,
		2014				2013
	Stock compensation expense recognized	$	1,350,243			$	538,643
	Weighted average grant-date fair value of stock options issued (per share)	$	2.68			$	2.29
	Grant-date fair value of stock options issued	$	1,343,817			$	4,266,120
	Intrinsic value of stock options exercised	$	32,892			$	2,566
	Volatility		114.4	%			117.7	%
	Risk-free interest rate		2	%			1.9	%
	Dividend yield		0	%			0	%
	Expected life in years		6.2				6.2

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	Loss before income taxes consisted of the following:
		Year ended December 31,
		2014			2013
	Domestic	$	-16,710,376		$	-20,038,881
	Foreign		-2,129,263			-2,217,576
	Total	$	-18,839,639		$	-22,256,457
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	A reconciliation of the Statutory United States federal income tax rate to the Company’s effective rate and for December 31, 2014 and 2013 is as follows:
		Year ended December 31,
		2014				2013
	Loss before income taxes	$	-18,839,639			$	-22,256,457
	Federal rate		34	%			34	%
	US Federal statutory tax rate		6,405,477				7,567,195
	State, net of federal rate		837,307				487,083
	Permanent differences		-1,030,698				-2,548,770
	Research and development tax credits		833,271				72,377
	Other		386,594				-113,803
	Changes to valuation allowances		-5,495,195				-4,051,780
		$	1,936,756			$	1,412,302
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Significant components of the Company’s total deferred tax asset as of December 31, 2014 and 2013 are as follows:
		December 31,
		2014			2013
	Net operating loss carry forwards	$	43,176,150		$	38,619,755
	Research and development loss pool carry forwards		3,512,452			3,865,195
	Deferred revenue		229,410			384,615
	Accrued expenses and other		440,342			287,272
	Stock based compensation		1,094,135			529,645
	Property and equipment		-267,909			-366,186
	R&D and investment tax credit carry forwards		1,125,434			494,523
	Deferred tax assets	$	49,310,014		$	43,814,819
	Deferred tax assets valuation allowance	$	-49,310,014		$	-43,814,819
		$	—		$	—

Geographic_Segment_Information1

Geographic Segment Information (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	The geographic information about total assets is based on the physical location of the assets.
		Total Assets
		December 31,
		2014		2013
	United States	$	34,027,837	$	26,190,516
	Canada		223,572		284,563
	Germany		867,694		997,671
	Total Assets	$	35,119,103	$	27,472,750
		Net Loss
		Year ended December 31,
		2014		2013
	United States	$	-14,773,620	$	-18,626,579
	Canada		-2,129,263		-2,217,576
	Total Net Loss	$	-16,902,883	$	-20,844,155

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	Minimum lease payments on all operating leases are as follows:
	Year ending December 31,
	2015	$	232,932
	2016		177,013
	2017		145,475
	2018		72,372
	Total	$	627,792

Nature_of_Business_and_Liquidi1

Nature of Business and Liquidity (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Nature Of Business And Liquidity [Line Items]
Accumulated deficit	($149,368,253)	($132,465,370)
Cash and Cash Equivalents, at Carrying Value	$32,413,777	$23,589,516	$9,648,008

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Certificates of Deposit		$15,003,472
Money Market Fund	29,500,819	7,597,730
Total		22,601,202
Fair Value, Inputs, Level 1 [Member]
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Certificates of Deposit		15,003,472
Money Market Fund	29,500,819	7,597,730
Total		22,601,202
Fair Value, Inputs, Level 2 [Member]
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Certificates of Deposit		0
Money Market Fund	0	0
Total		0
Fair Value, Inputs, Level 3 [Member]
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Certificates of Deposit		0
Money Market Fund	0	0
Total		$0

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Significant Accounting Policies Disclosure [Line Items]
Money Market Funds, at Carrying Value	29,500,819	$7,597,730
Computer Equipment [Member]
Significant Accounting Policies Disclosure [Line Items]
Property, Plant and Equipment, Useful Life	4 years
Furniture and office equipment [Member]
Significant Accounting Policies Disclosure [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Laboratory Equipment [Member]
Significant Accounting Policies Disclosure [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Capita lLease Equipment And Leasehold Improvements [Member]
Significant Accounting Policies Disclosure [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	Lesser of useful life or term of lease

Other_Receivables_Details

Other Receivables (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Other Receivables [Line Items]
Receivables related to the sale of New Jersey net operating losses	$0	$1,412,302
Other receivables	21,102	5,011
Other receivables, net	$21,102	$1,417,313

Other_Current_Assets_Details

Other Current Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Other Current Assets [Line Items]
Clinical trial materials	$458,278	$468,389

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$2,157,239	$2,186,900
Less: Accumulated depreciation	-1,152,827	-1,048,321
Property and equipment, net	1,004,412	1,138,579
Computer and equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	144,138	136,498
Furniture and office equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	96,457	96,457
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,723,331	1,760,633
Capital lease equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	155,524	155,523
Leaseholds [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$37,789	$37,789

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Feb. 29, 2012
Property, Plant and Equipment [Line Items]
Proceeds from sale of assets	$0	$51,776
Loss on disposal of property and equipment	77,624	126,633
Depreciation And Amortization	195,492	197,743
Other Property and Equipment [Member]
Property, Plant and Equipment [Line Items]
Loss on disposal of property and equipment	3,538	582
Assets Held for Sale [Member]
Property, Plant and Equipment [Line Items]
Assets Held For Sale Long Lived			507,622
Assets Disposals, Written Off Net Book Value		177,827
Proceeds from sale of assets		51,776
Loss on disposal of property and equipment		126,051
Gain (Loss) on Sale of Assets and Asset Impairment Charges	$74,086

Other_Assets_Details

Other Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Other Assets Noncurrent [Line Items]
Deferred financing costs (see Note 8)	$539,296	$0
Other non-current assets	5,205	5,745
Assets, Noncurrent	$544,501	$5,745

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accrued Liabilities [Line Items]
Accrued bonuses	$816,144	$624,472
Accrued salaries and vacation	152,700	143,484
Accrued professional fees	8,904	30,911
Accrued clinical trial expenses	633,395	636,497
Interest payable	83,958	0
Accrued other	40,319	195,445
Accrued liabilities	$1,735,420	$1,630,809

Loans_Payable_Details

Loans Payable (Details) (USD $)	Dec. 31, 2014
Schedule Of Loan payable [Line Items]
Loan payable	$10,000,000
End of term fee	121,217
Long-term debt	10,121,217
Less: Current portion	-284,961
Long-term debt	$9,836,256

Loans_Payable_Details_Textual

Loans Payable (Details Textual) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	9-May-14
Schedule Of Loan payable [Line Items]
Amortization Of Financing Costs And Discounts	$259,926	$74,752
Adjustments to Additional Paid in Capital, Warrant Issued	320,752
Deferred Finance Costs, Noncurrent, Net	539,296	0
Hercules Technology Growth Capital [Member]
Schedule Of Loan payable [Line Items]
Line of Credit Facility, Fair Value of Amount Outstanding			10,000,000
Line of Credit Facility, Maximum Borrowing Capacity			15,000,000
Line of Credit Facility, Remaining Borrowing Capacity			5,000,000
Long-term Debt, Maturities, Repayment Terms			repayable in installments over forty-eight months including an initial interest-only period of eighteen months after closing
Line of Credit Facility, Interest Rate Description			Interest is payable monthly at the greater of 9.75% or an adjusted rate based upon the US prime rate with interest only period until December 1, 2015.
Warrants Maturity Term	5 years
End of Loan Term, Fees	121,217
Hercules Technology Growth Capital [Member] | Warrant [Member]
Schedule Of Loan payable [Line Items]
Stock Issued During Period, Shares, New Issues	158,006
Amortization Of Financing Costs And Discounts	138,709
Class of Warrant or Right, Exercise Price of Warrants or Rights	$2.67
Adjustments to Additional Paid in Capital, Warrant Issued	320,752
Deferred Finance Costs, Noncurrent, Net	539,296
Hercules Technology Growth Capital [Member] | Term Loan [Member]
Schedule Of Loan payable [Line Items]
Debt Issuance Cost	357,253
Hercules Technology Growth Capital [Member] | End of Term Fee [Member]
Schedule Of Loan payable [Line Items]
Debt Issuance Cost	$592,500

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Number of warrants	5,440,480
March 2009 [Member]
Number of warrants	12,445
Exercise price	$11.25
Warrants Maturity Term	7 years
December 2011 [Member]
Number of warrants	123,585
Exercise price	$5.21
Warrants Maturity Term	7 years
February 2012 [Member]
Number of warrants	3,700
Exercise price	$5.21
Warrants Maturity Term	6 years
June 2012 [Member]
Number of warrants	17,267
Exercise price	$5.21
Warrants Maturity Term	7 years
August 2012 [Member]
Number of warrants	112,536
Exercise price	$5.21
Warrants Maturity Term	7 years
April 2013 [Member]
Number of warrants	161,327
Exercise price	$5.21
Warrants Maturity Term	7 years
April 2013 One [Member]
Number of warrants	3,977,290
Exercise price	$3.58
Warrants Maturity Term	7 years
May 2014 [Member]
Number of warrants	158,006
Exercise price	$2.67
Warrants Maturity Term	5 years
October 2014 [Member]
Number of warrants	874,324
Exercise price	$3.58
Warrants Maturity Term	5 years

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Apr. 29, 2013	Oct. 28, 2014
Schedule Of Shareholders Equity [Line Items]
Proceeds From Issuance Of Common Stock	$14,929,892	$32,520,974
Common Stock Shares Issued	33,681,355	26,035,596
Private Placement [Member]
Schedule Of Shareholders Equity [Line Items]
Stock Issued During Period, Shares, New Issues			10,430,034
Sale of Stock, Price Per Share			$3.12
Gross proceeds from issuance of private placement			32,499,986
Class of Warrant or Right, Exercise Price of Warrants or Rights			$3.58
Proceeds from Issuance of Private Placement			29,420,375
Private Placement [Member] | Warrant [Member]
Schedule Of Shareholders Equity [Line Items]
Warrants Conversion Ratio			$0.28
Private Placement [Member] | Warrants Exercise Price at $3.58 [Member]
Schedule Of Shareholders Equity [Line Items]
Warrants Issued For Purchase Of Common Stock	1,056,898
Class of Warrant or Right, Exercise Price of Warrants or Rights	$3.58
Derivative Liability, Fair Value, Gross Liability	7,473,108
Private Placement [Member] | Warrants Exercise Price at $5.21 [Member]
Schedule Of Shareholders Equity [Line Items]
Warrants Issued For Purchase Of Common Stock	161,327
Class of Warrant or Right, Exercise Price of Warrants or Rights	$5.21
Common Stock Shares Issued	1,923,599
Public Offering [Member] | Warrant [Member]
Schedule Of Shareholders Equity [Line Items]
Stock Issued During Period, Shares, New Issues				760,282
Public Offering [Member] | Common Stock [Member]
Schedule Of Shareholders Equity [Line Items]
Stock Issued During Period, Shares, New Issues				7,602,823
Public Offering [Member] | Underwriters [Member] | Warrant [Member]
Schedule Of Shareholders Equity [Line Items]
Stock Issued During Period, Shares, New Issues				114,042
Proceeds From Issuance Of Common Stock				13,600,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				3.58
Warrants Maturity Term				5 years
Public Offering Over Allotment Option [Member] | Warrant [Member]
Schedule Of Shareholders Equity [Line Items]
Stock Issued During Period, Shares, New Issues				99,167
Public Offering Over Allotment Option [Member] | Common Stock [Member]
Schedule Of Shareholders Equity [Line Items]
Stock Issued During Period, Shares, New Issues				991,673

Stock_Based_Compensation_Detai

Stock Based Compensation (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Share Based Compensation Stock Options Activity [Line Items]
Number of options, Beginning balance	2,578,252	806,788
Number of options, Granted	502,100	1,864,559
Number of options, Exercised	-42,936	-8,803
Number of options, Cancelled	-32,129	-84,292
Number of options, Ending balance	3,005,287	2,578,252
Number of options, Exercisable	1,352,056
Exercise price, Beginning balance	$2.98	$2.52
Exercise price, Granted	$3.13	$3.18
Exercise pice, Exercised	$2.34	$2.81
Exercise price, Cancelled	$2.97	$2.98
Exercise price, Ending balance	$3.02	$2.98
Exercise price, Exercisable	$2.82
Weighted Average Remaining Contractual Life, Outstanding (in Years)	7 years 2 months 12 days
Weighted Average Remaining Contractual Life, Exercisable (in Years)	5 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding	$9,801
Aggregate Intrinsic Value, Exercisable	$9,771

Stock_Based_Compensation_Detai1

Stock Based Compensation (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding	3,005,287
Options Outstanding, Weighted Average Exercise Price	$3.02
Options Outstanding, Weighted Average Remaining Contractual Life (In Years)	7 years 2 months 12 days
Number of Options Exercisable	1,352,056
Options Exercisable, Weighted Average Exercise Price	$2.82
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, Upper Limit	$1.95
Exercise Price Range, Lower Limit	$1.12
Number of Options Outstanding	14,632
Options Outstanding, Weighted Average Exercise Price	$1.29
Options Outstanding, Weighted Average Remaining Contractual Life (In Years)	6 years 7 months 6 days
Number of Options Exercisable	11,632
Options Exercisable, Weighted Average Exercise Price	$1.12
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, Upper Limit	$3.40
Exercise Price Range, Lower Limit	$2.25
Number of Options Outstanding	2,672,246
Options Outstanding, Weighted Average Exercise Price	$2.96
Options Outstanding, Weighted Average Remaining Contractual Life (In Years)	7 years
Number of Options Exercisable	1,258,100
Options Exercisable, Weighted Average Exercise Price	$2.79
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, Upper Limit	$3.80
Exercise Price Range, Lower Limit	$3.47
Number of Options Outstanding	318,409
Options Outstanding, Weighted Average Exercise Price	$3.52
Options Outstanding, Weighted Average Remaining Contractual Life (In Years)	8 years 10 months 24 days
Number of Options Exercisable	82,324
Options Exercisable, Weighted Average Exercise Price	$3.51

Stock_Based_Compensation_Detai2

Stock Based Compensation (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Summary Of Unvested Awards Activity [Line Items]
Number of options, Begining balance	1,810,203
Number of options, Granted	502,100	1,864,559
Number of options, Vested	-659,072
Number of options, Ending balance	1,653,231	1,810,203
Grant date fair value, Begining balance	$4,146,515
Grant date fair value, Granted	$1,343,817
Grant date fair value, Vested	($1,478,969)
Grant date fair value, Ending balance	$4,011,363	$4,146,515

Stock_Based_Compensation_Detai3

Stock Based Compensation (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock compensation expense recognized	$1,350,243	$538,643
Weighted average grant-date fair value of stock options issued (per share)	$2.68	$2.29
Grant-date fair value of stock options issued	1,343,817	4,266,120
Intrinsic value of stock options exercised	$32,892	$2,566
Volatility	114.40%	117.70%
Risk-free interest rate	2.00%	1.90%
Dividend yield	0.00%	0.00%
Expected life in years	6 years 2 months 12 days	6 years 2 months 12 days

Stock_Based_Compensation_Detai4

Stock Based Compensation (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,200,560
2013 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		0
Non vested Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$3,641,722
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 7 months 6 days

Benefit_Plans_Details_Textual

Benefit Plans (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014
Defined Contribution Plan, Employer Discretionary Contribution Amount	$111,509
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	50.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	6.00%

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]
Domestic	($16,710,376)	($20,038,881)
Foreign	-2,129,263	-2,217,576
Total	($18,839,639)	($22,256,457)

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Effective Income Tax Rate Reconciliation [Line Items]
Loss before income taxes	($18,839,639)	($22,256,457)
Federal rate	34.00%	34.00%
US Federal statutory tax rate	6,405,477	7,567,195
State, net of federal rate	837,307	487,083
Permanent differences	-1,030,698	-2,548,770
Research and development tax credits	833,271	72,377
Other	386,594	-113,803
Changes to valuation allowances	-5,495,195	-4,051,780
Income tax benefit	$1,936,756	$1,412,302

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Effective Income Tax Rate Reconciliation [Line Items]
Net operating loss carry forwards	$43,176,150	$38,619,755
Research and development loss pool carry forwards	3,512,452	3,865,195
Deferred revenue	229,410	384,615
Accrued expenses and other	440,342	287,272
Stock based compensation	1,094,135	529,645
Property and equipment	-267,909	-366,186
R&D and investment tax credit carry forwards	1,125,434	494,523
Deferred tax assets	49,310,014	43,814,819
Deferred tax assets valuation allowance	-49,310,014	-43,814,819
Deferred Tax Assets, Net of Valuation Allowance, Total	$0	$0

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]
Income tax benefit	$1,936,756	$1,412,302
Canadian Federal [Member]
Income Taxes [Line Items]
Investment Tax Credit	450,999	494,523
Federal Income Tax Purposes [Member] | Research Tax Credit Carryforward [Member]
Income Taxes [Line Items]
Tax Credit Carryforward, Amount	674,435
Foreign Tax Authority [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	124,704,785
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	$15,530,804

Geographic_Segment_Information2

Geographic Segment Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	$35,119,103	$27,472,750
Total Net Loss	-16,902,883	-20,844,155
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	34,027,837	26,190,516
Total Net Loss	-14,773,620	-18,626,579
Canadian Federal [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	223,572	284,563
Total Net Loss	-2,129,263	-2,217,576
Germany [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	$867,694	$997,671

Leukemia_and_Lymphoma_Society_1

Leukemia and Lymphoma Society funding (Details Textual) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2012
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront payment, recorded as deffered revenue	$542,986	$542,986
Leukemia And Lymphoma Society Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront payment, recorded as deffered revenue			2,000,000
Potential Future Milestone Payments			3,000,000
Revenue Recognition, Milestone Method, Revenue Recognized	1,000,000
Recognition of Deferred Revenue	542,986	561,086
Leukemia And Lymphoma Society Agreement [Member] | Phase Three Study [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Funding for project inventions	$5,000,000		$5,000,000

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	Dec. 31, 2014
Lease Payments [Line Items]
2015	$232,932
2016	177,013
2017	145,475
2018	72,372
Total	$627,792

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Textual) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2012
Loss Contingencies [Line Items]
Rectification of default period	60 months
Operating Leases, Future Minimum Payments Due, Total	$627,792
Operating Leases, Rent Expense	221,867	246,784
Princeton University Agreement [Member]
Loss Contingencies [Line Items]
Agreement termination notice period	90 days
Rectification of default period	60 days
Leukemia & Lymphoma Society Agreement [Member]
Loss Contingencies [Line Items]
Percentage of royalty payable from the amount received from out-licenses and transfers	50.00%
Number of times amount payable under research funding program	1.5
Cash Payment Or Royalties on net sales	5.00%
Leukemia & Lymphoma Society Agreement [Member] | Phase 3 study [Member]
Loss Contingencies [Line Items]
Funding for project inventions	5,000,000		5,000,000
Leukemia & Lymphoma Society Agreement [Member] | Phase 2 study [Member]
Loss Contingencies [Line Items]
Funding for project inventions	4,100,000
Vancouver Laboratory Space, British Columbia [Member]
Loss Contingencies [Line Items]
Operating Leases, Future Minimum Payments Due, Total	25,087
Ewing, New Jersey [Member]
Loss Contingencies [Line Items]
Operating Leases, Future Minimum Payments Due, Total	495,840
Letters of Credit Outstanding, Amount	200,000
Contractual Obligation of letter of credit payment as on December 1, 2014	40,000
Contractual Obligation of letter of credit payment as on December 1, 2015	40,000
Contractual Obligation of letter of credit payment as on December 1, 2016	40,000
Contractual Obligation of letter of credit payment as on December 1, 2017	60,000
Vancouver Office Space, British Columbia [Member]
Loss Contingencies [Line Items]
Operating Leases, Future Minimum Payments Due, Total	$93,292
British Columbia Cancer Agency [Member]
Loss Contingencies [Line Items]
Rectification of default period	45 days
Minimum [Member] | Princeton University Agreement [Member]
Loss Contingencies [Line Items]
Percentage of royalty payable from the amount received from out-licenses and transfers	45.00%
Maximum [Member] | Princeton University Agreement [Member]
Loss Contingencies [Line Items]
Percentage of royalty payable from the amount received from out-licenses and transfers	55.00%
Maximum [Member] | Leukemia & Lymphoma Society Agreement [Member]
Loss Contingencies [Line Items]
Number of times amount payable under research funding program	3.55